Drug intelligence / Profile preview

IT-901

Development stage: Unknown
Modality: Small Molecules
Administration: In Vitro

Overview

IT-901 is a small molecule inhibitor targeting the **NF-κB subunit c-Rel**. It selectively inhibits NF-κB DNA binding (IC50 = 0.1 μM in HBL1 cells) and reduces TNF-α-induced NF-κB activity. NF-κB/c-Rel is implicated in the regulation of immune response and oncogenesis, making IT-901 a candidate for cancer and immunology research. The compound has a chemical structure of 5-((2,4-dimethoxynaphthalen-1-yl)methylene)-2-thioxodihydropyrimidine-4,6(1H,5H)-dione and a molecular formula of C17H14N2O4S[1][3].

Targets

RELA (Nuclear Factor Kappa B Subunit p65)REL (Proto-oncogene c-Rel)

Beyond the preview

Go deeper on IT-901.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IT-901.

Explore the full profile